Program
INI-2004
A development code.
Its studies are mostly in Rhinitis, Allergic, Perennial · Rhinitis, Allergic, led by Inimmune.
Furthest: phase 2, since Jan 15, 20262 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Inimmune | 20 open or running | phase 2since Jan 15, 2026 | Jul 31, 2023 | none ahead |
Also a collaborator on its studies: rho-inc and avance-clinical-pty-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 31, 2023First study: phase 1 study in Rhinitis, AllergicFirst studyNCT06038279 · 68 enrolled · Australia
- Jan 15, 2026Phase 2 study in Rhinitis, Allergic, PerennialPhase 2 reachedNCT07556393 · 78 enrolled · Canada
TargetBeta
TLR4 →read by rule
“INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.”study text, by rule · the study
Other programs on TLR4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| NI-0101rule | ppd-development-lp | phase 3 | 4 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07556393Rhinitis, Allergic, Perennial · Canada | 2 | Completed | Apr 23, 2026 | 78 |
| NCT06038279Rhinitis, Allergic · Australia | 1 | Completed | Sep 5, 2024 | 68 |
How it is read
Names in the registry
- “INI-2004”, 2 entries
Codes read as this program: INI2004.
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Perennial, 1 study
- Rhinitis, Allergic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.